Drug intelligence / Profile preview

CBT401

Development stage: Preclinical
Lead developer: CERES BRAIN Therapeutics
Modality: Small Molecules
Administration: Intranasal

Overview

CBT401 is an investigational small molecule therapy being developed by Ceres Brain Therapeutics for the treatment of glucose transporter type 1 deficiency syndrome (GLUT1DS, also known as De Vivo disease). Administered intranasally via the company's proprietary 'Nose-to-Neurons' delivery platform, CBT401 is designed to bypass the blood-brain barrier and deliver glucose and creatine directly to neurons. This dual-targeting approach aims to restore cellular energy homeostasis and alleviate neurological symptoms associated with impaired glucose transport in the brain.

Targets

GLUT1 (Glucose transporter 1)SLC6A8 (Sodium- and chloride-dependent creatine transporter 1)

Beyond the preview

Go deeper on CBT401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBT401.

Explore the full profile